Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels - PubMed (original) (raw)
Clinical Trial
Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels
L J Gooren et al. Andrologia. 2008 Oct.
Abstract
The study was performed to measure the impact of testosterone (T) administration on circulating levels of 5alpha-dihydrotestosterone (DHT). Group 1 (32 men; mean age 61 years; mean T 6.9 +/- 1.9 nmol l(-1)) were treated for 15 months with long-acting T undecanoate. Group 2 (23 men, mean age 60 years, mean T 7.6 +/- 2.0 nmol l(-1)) were treated for 9 months with T gel. Plasma T and DHT were measured before and after 9 months T administration. In the men treated with T undecanoate plasma T and DHT were also measured after 12 and 15 months. Before T administration, plasma DHT ranged from 0.39 to 1.76 nmol l(-1) (0.30-1.90 nmol l(-1)). Mean DHT declined upon T administration from 0.95 +/- 0.50 to 0.55 +/- 0.30 nmol l(-1) (P < 0.05). With an arbitrary cut-off at 0.60 nmol l(-1), all 21 values of DHT > 0.60 nmol l(-1) had fallen from 1.29 +/- 0.50 to 0.70 +/- 0.60 nmol l(-1) (P < 0.01). Below this cut-off point 13 values rose and 21 fell upon T administration. Below this cut-off point values on average declined from 0.39 +/- 0.12 to 0.30 +/- 0.14 nmol l(-1) (P < 0.05). The study revealed that in a cohort of elderly men with subnormal plasma T levels plasma DHT levels declined upon T administration when they were in the higher range of normal (>0.6 nmol l(-1)), with a profound shift of DHT/T ratios presumed to be an indicator of a reduced 5alpha-reductase activity. Below plasma DHT levels of 0.6 nmol l(-1), responses of plasma DHT to T administration varied.
Similar articles
- Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
Yassin AA, Saad F. Yassin AA, et al. Andrologia. 2007 Oct;39(5):181-4. doi: 10.1111/j.1439-0272.2007.00785.x. Andrologia. 2007. PMID: 17714216 Clinical Trial. - Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Jockenhövel F, et al. Eur J Med Res. 1997 Jul 28;2(7):293-8. Eur J Med Res. 1997. PMID: 9233903 Clinical Trial. - Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C, Harnett M, Dobs AS, Swerdloff RS. Wang C, et al. J Androl. 2010 Sep-Oct;31(5):457-65. doi: 10.2164/jandrol.109.009597. Epub 2010 Feb 4. J Androl. 2010. PMID: 20133964 Clinical Trial. - Transdermal dihydrotestosterone treatment of 'andropause'.
de Lignieres B. de Lignieres B. Ann Med. 1993 Jun;25(3):235-41. doi: 10.3109/07853899309147869. Ann Med. 1993. PMID: 7687444 Review. - More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. Saad F, et al. Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x. Asian J Androl. 2007. PMID: 17486268 Review.
Cited by
- Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.
Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Borst SE, et al. BMC Med. 2014 Nov 27;12:211. doi: 10.1186/s12916-014-0211-5. BMC Med. 2014. PMID: 25428524 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical